UBS Group’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,000
| Closed | -$2.4K | – | 11227 |
|
|
2025
Q1 | $2.4K | Buy |
2,000
+1,476
| +282% | +$9.03K | ﹤0.01% | 9340 |
|
|
2024
Q4 | $4.98K | Sell |
524
-293
| -36% | -$3.89K | ﹤0.01% | 8707 |
|
|
2024
Q3 | $14.2K | Buy |
817
+774
| +1,800% | +$19.2K | ﹤0.01% | 7550 |
|
|
2024
Q2 | $562 | Buy |
+43
| New | +$2.1K | ﹤0.01% | 8866 |
|
|
2024
Q1 | – | Sell |
-26
| Closed | -$2.12K | – | 10347 |
|
|
2023
Q4 | $2.12K | Buy |
+26
| New | +$3.89K | ﹤0.01% | 8162 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 8903 |
|
|
2023
Q1 | – | Sell |
-47
| Closed | -$7.35K | – | 10871 |
|
|
2022
Q4 | $7.35K | Buy |
47
+22
| +88% | +$5.01K | ﹤0.01% | 8906 |
|
|
2022
Q3 | $7K | Buy |
+25
| New | +$9K | ﹤0.01% | 8936 |
|
|
2022
Q1 | – | Sell |
-46
| Closed | -$39K | – | 11156 |
|
|
2021
Q4 | $39K | Buy |
+46
| New | +$47.4K | ﹤0.01% | 7164 |
|
|
2021
Q3 | – | Sell |
-16
| Closed | -$18K | – | 10282 |
|
|
2021
Q2 | $18K | Buy |
16
+4
| +33% | +$4.3K | ﹤0.01% | 7464 |
|
|
2021
Q1 | $14K | Buy |
+12
| New | +$16.1K | ﹤0.01% | 7692 |
|
Other funds holding VRPX
UBS Group's VRPX Position: Q2 2025 in Review
UBS Group sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q2 2025, closing a stake of 2,000 shares — an estimated $2.4K sold.
UBS Group first reported a position in VRPX in Q1 2021 and held it in 10 quarters. The position peaked at $39K in Q4 2021. 1 fund tracked by Wall St. Rank holds VRPX as of Q2 2025.
- UBS Group reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 2,000 Virpax Pharmaceuticals, Inc. Common Stock shares in Q2 2025, an estimated $2.4K.
- UBS Group first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
- UBS Group's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $39K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.